Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?

Clin Chem. 2015 Oct;61(10):1235-40. doi: 10.1373/clinchem.2015.238105. Epub 2015 Aug 13.

¹ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada;
² Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Clinical Biochemistry, University Health Network; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; ediamandis@mtsinai.on.ca.
³ Director of Pharmacogenomics & Personalized Therapeutics, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai School, New York, NY;
⁴ Professor of Medicine, Physiology and Pharmacology, and Oncology, Wolfe Medical Research, Chair in Pharmacogenomics, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada;
⁵ Program Director, Adult Interventional Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

No abstract available

Publication types